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Purpose: Retinoblastoma, a childhood cancer of the retina, is caused by inactivation of the tumor suppressor gene
retinoblastoma (RB). Cotylenin A (CN-A), a novel fusicoccane-diterpene glycoside, accelerates the differentiation of
several types of myeloid cell lines and is a candidate for a new type of anticancer therapeutic agent with this effect.
However, whether CN-A has the same effect on retinoblastoma cells is unknown. We studied the response of two
retinoblastoma cell lines, Y-79 and WERI-Rb-1, to CN-A.
Methods: We studied the response of two retinoblastoma cell lines to CN-A with respect to cell growth, apoptosis,
morphology, mRNA, protein expression analysis of specific genes (N-myc, cyclin-dependent kinase inhibitor 1A [P21],
paired box gene 6 [PAX6], and rhodopsin [RHO]), and activity of three PAX6 promoters (P0, P1, and Pα).
Results: CN-A inhibited cell proliferation and induced apoptosis via caspase activity in the two retinoblastoma cell lines.
In addition, CN-A induced mRNA expression of P21, PAX6, and RHO and protein expression of P21. In Y-79 cells,
PAX6 P1 promoter was activated by CN-A. In WERI-Rb-1 cells, PAX6 P0, P1, and Pα promoter were activated by CN-
A. CN-A decreased mRNA and protein expression of N-myc in two retinoblastoma cell lines.
Conclusions: The responses of retinoblastoma cells to CN-A include inhibition of cell growth, induction of apoptosis,
and the potential to change neuroblastoma characteristics of retinoblastoma cells.
Retinoblastoma, a childhood cancer of the retina [1], is
caused by an inheritable mutation of the tumor suppressor
gene retinoblastoma (RB) [2]. Retinoblastoma has bipotential
differentiation  status  and  Müller-  and  photoreceptor-like
characters [3]. Recently, the possibility that retinoblastoma
results from a mixture of transformed retinal progenitor and
transition cells was suggested [4]. Although the inactivation
of  the  two  RB  alleles  is  the  most  important  event  in  the
oncogenesis  of  retinoblastoma,  other  oncogenes  or  tumor
suppressor  genes  may  also  be  involved  in  the  aggressive
progression  of  this  tumor.  Various  therapies  (e.g.,
chemotherapy,  cryotherapy,  thermotherapy,  and  radiation
therapy) have been used to cure retinoblastoma [5].
Cotylenin  A  (CN-A),  a  novel  fusicoccane-diterpene
glycoside  isolated  from  the  culture  filtrate  of  a  fungus
(Cladosporium  sp.),  is  a  plant  growth  regulator  with
cytokinin-like activity [6–8]. CN-A, which also has the ability
to induce differentiation in several human and murine myeloid
leukemia  cell  lines  [9,10],  significantly  stimulated  both
functional and morphologic differentiation of leukemic cells
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in nine of 12 cases [11]. It has been reported that the cptylenin
A- induced differentiation of human leukemia cell lines is
independent of the transforming growth factor-beta signaling
system [12]. Combined treatment with interferon-α (IFN-α)
and CN-A has induced apoptosis of human lung cancer cells
[13]. In addition, this treatment has significantly inhibited the
growth  of  both  xenografted  lung  cancer  cells,  without
apparent  adverse  side  effects  [13],  and  primary  ovarian
carcinoma cells [14]. Combined treatment with rapamycin
and CN-A inhibited cell growth in breast carcinoma in vitro
and in vivo [15]. Thus, CN-A is among the unique agents that
accelerate  cell  differentiation  [16].  Recently,  CN-A  was
reported to be a molecule that binds to a 14–3–3 regulator
protein complex [17]. However, whether CN-A has this effect
on retinoblastoma cells is not known.
In this study, we examined the effect of CN-A on the
proliferation and differentiation of human retinoblastoma cell
lines Y-79 and WERI-Rb-1 (WERI) [18,19] to investigate
whether retinoblastoma cells also respond to CN-A.
METHODS
Cell culture: Retinoblastoma cell lines Y-79 and WERI were
obtained  from  the  American  Type  Culture  Collection
(Manassas,  VA).  Y-79  and  WERI  cells  were  cultured  on
Roswell  Park  Memorial  Institute  (RPMI)  1640  medium
(Invitrogen,  Carlsbad,  CA)  containing  10%  fetal  bovine
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970serum (JRA Bioscience, Lenexa, KS). Cells were grown in a
humidified 5% CO2 atmosphere at 37 °C.
Cotylenin A: CN-A was purified from the ethyl acetate extract
of the culture filtrate of Cladosporium 501–7W [7,8]. CN-A
was  dissolved  in  dimethyl  sulfoxide  at  a  20-mg/ml
concentration and then added to the medium at concentrations
of 0, 10, or 20 μg/ml. Dimethyl sulfoxide at concentrations up
to 0.1% had no effect on cell proliferation, gene expression,
or morphology when added with or without CN-A.
Assay  of  cell  growth:  Cell  Titer-Blue  Assay  (Promega,
Madison,  WI)  was  used  to  evaluate  cell  growth.  Cells
(1.0×105 cells/ml) were cultured with 0, 10, or 20 μg/ml CN-
A for 0, 3, and 7 days in 96-well plates (CELLSTAR®; Greiner
Bio-One, Frickenhausen, Germany). Then, 20 μl of the Cell
Titer-Blue  Assay  solution  was  added,  and  the  cells  were
incubated for 2 h at 37 °C and 5% CO2. Fluorescence (560/590
nm)  was  measured  using  a  Gemini  EM  microplate
spectrofluorometer (Molecular Devices, Sunnyvale, CA). The
Mann–Whitney U-test (n=3) was used for statistical analysis.
Terminal deoxyribonucleotidyl transferase (TdT) -mediated
deoxyuridine 5′-triphosphate -biotin nick-end labeling assay
(TUNEL) assay: Cells (1.0×105 cells/ml) were incubated with
or  without  10  μg/ml  CN-A  for  7  days  in  six-well  plates
(CELLSTAR®). At the end of the treatment, the cells were
washed with PBS (137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4/KH2PO4, pH 7.4.) and centrifuged for 5 min at 500×
g  for  microscope  slide  cell  preparations.  We  used  the
Apoptosis  In  Situ  Detection  Kit  (Wako  Pure  Chemical
Industries, Osaka, Japan) to evaluate cell apoptosis. Cells
were fixed with 4% formalin neutral-buffered solution for 10
min. The 3′ terminals of DNA fragments, which in TUNEL
positive  cells  was  labeled  by  TdT  protein,  Peroxidase-
conjugated TdT antibody and 3,3′-diaminobenzidine (DAB).
The samples were covered with Soft Mounting Media (Wako
Pure Chemical Industries) and observed with a laser scanning
microscope  (LSM-510  Meta;  Carl  Zeiss  MicroImaging,
Thornwood, NY). Under the microscope, the total number of
cells  in  25  random  fields  per  condition  was  counted:
incidence=terminal  transferase  uridyl  nick  end  labeling
(TUNEL)-positive cells/all cells. The Mann–Whitney U-test
(n=3) was used for statistical analysis.
Observation of morphological changes and cell counting: For
morphological examination, cells were cultured in poly-D-
lysine-coated  tissue  culture  vessels  (CELLSTAR®).  Cells
were examined and photographed using a Leica DMI3000B
inverted microscope (Leica, Wetzlar, Germany). Under the
microscope, the total number of cells in ten random fields per
condition was counted: dendrite-like process cells/all cells.
The  Mann–Whitney  U-test  (n=3)  was  used  for  statistical
analysis.
Reverse-transcriptase  PCR  analysis:  Total  RNA  was
prepared by disrupting the cells in ISOGEN reagent (Nippon
Gene, Toyama, Japan), and isopropanol precipitation. Total
RNA  (2  μg)  was  reverse  transcribed  with  200  U  reverse
transcriptase (Promega), 0.5 μg oligo (dT)16 primer, and 20 U
RNase inhibitor (Takara Bio, Shiga, Japan) for 60 min. PCR
amplifications  were  performed  in  25-μl  reaction  mixtures
containing  1.5  μl  of  the  resulting  cDNA,  200  μM
deoxycytidine triphosphate (adenine, cytosine, guanine, and
thymine) mixture (dNTP), 1 μM primers, and 1 U KOD® plus
(Toyobo, Osaka, Japan). The resulting cDNAs were amplified
using a KOD-Plus-PCR Kit (Toyobo) in 25 µl of medium.
Primer sequences are detailed in Table 1. The PCR schedule
was as follows: 1 min at 95 °C, followed by 20 (β-actin;
ACTB)  or  25–35  cycles,  depending  on  the  primer  (other
experiments); 15 s at 94 °C, 30 s at 60 °C or 55–65 °C,
depending  on  the  primer  (other  experiments);  and  a  final
extension step of 30 s at 68 °C and 1.5 min at 68 °C. Annealing
temperatures and the number of PCR cycles are detailed in
Table 1.
The PCR products were separated using 2% agarose gel
(Iwai  Chemicals,  Tokyo,  Japan)  electrophoresis  and
visualized  via  ethidium  bromide  staining.  Results  were
quantified using CS Analyzer software (ATTO Corporation,
Tokyo, Japan).
Western blot: Cells (1.0×105 cells/ml) were incubated with or
without  10  μg/ml  CN-A  for  5  days  in  six-well  plates
(CELLSTAR®). Cells were collected and lysed in sample
radio immunoprecipitation assay (RIPA) buffer (50 mM Tris-
HCl [pH 8.0], 150 mM NaCl, 1 mM EDTA, 1% Triton X-100,
0.1%  sodium  dodecyl  sulfate  [SDS],  0.1%  sodium
deoxycholate)  with  an  added  protease  inhibitor  cocktail
(Roche  Diagnostics,  Basel,  Switzerland)  and  1  mM
phenylmethylsulphonyl  fluoride  (Wako  Pure  Chemical
Industries) at 4 °C. After sonication in ice water, crude lysates
were cleared via centrifugation at 22,000× g for 30 min at 4 °C.
The total protein concentration of the lysates was measured
using the Bradford assay. Lysate aliquots were diluted at a 3:1
ratio with sample buffer (50 mM Tris-HCl [pH 6.8], 10%
weight/volume [w/v] SDS, 10% v/v glycerol, 10% v/v 2-
mercaptoethanol, 0.02% w/v bromophenol blue) and boiled 2
min. Equal amounts of protein (40–50 μg) were loaded onto
10% and 12.5% SDS-polyacrylamide gels and subjected to
electrophoresis.  The  separated  proteins  were  then
electrotransferred  to  polyvinylidene  fluoride  (PVDF)
membranes  (Immun-Blot®  PVDF  membrane;  Bio-Rad,
Hercules,  CA).  Following  electrotransfer,  the  blots  were
incubated for 60 min in a blocking solution (0.3% w/v dried
low-fat milk/Tris-buffered saline) on an orbital shaker. The
primary antibodies used in the blocking solution were anti-
rhodopsin (antimouse; Sigma-Aldrich, St. Louis, MO); 1 μg/
ml anti-PAX6 (antirabbit #PRB-278P; Covance, Princeton,
NJ);  anti-N-myc  diluted  1:500  (antirabbit  #9405;  Cell
Signaling  Technology,  Beverly,  MA);  anti-cleaved-poly
(ADP-ribose) polymerase (PARP) diluted 1:500 (antirabbit
#9541;  Cell  Signaling  Technology);  1  μg/ml  anti-cyclin-
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972dependent  kinase  inhibitor  1A  (P21,  #556430;  BD
Biosciences, San Jose, CA); anti-acetyl histone H3 diluted
1:1,000 (antirabbit #9671; Cell Signaling Technology); anti-
acetyl  histone  H4  diluted  1:1,000  (antirabbit  #2594;  Cell
Signaling  Technology);  20  ng/ml  anti-β-actin  (antimouse
#A5316; Sigma-Aldrich), and 1 μg/ml secondary horseradish
peroxidase  conjugate  (mouse  and  rabbit;  GE  Healthcare,
Little  Chalfont,  UK).  The  ECL™  Plus  Western  Blotting
Detection System (GE Healthcare) was used for detection.
Results were quantified using CS Analyzer software. The
Mann–Whitney U-test (n=3) was used for statistical analysis.
Promoter  assay:  The  pGL4.10-promoter  vector  was
constructed  using  designed  primers  (Table  1)  and  the
restriction enzymes KpnI and Nhe I. Cells were seeded in
duplicate into 24-well plates (CELLSTAR®) at a density of
1×105 cells/well with growth medium. After 24 h, cells were
transfected for 16 h with pGL4.10-promoter constructs and
pGL4.74  plasmid  (Promega)  as  an  internal  control  for
transfection  efficiency  using  FuGENE  HD  (Roche
Diagnostics). Cells were treated with or without 10 μg/ml CN-
A for 48 h. Luciferase activity in cells was measured using the
Dual-Luciferase  Reporter  Assay  System  (Promega)  with
luminometer LB9507 (Berthold Technologies, Bad Wildbad,
Germany). The Mann–Whitney U-test (n=3) was used for
statistical analysis.
RNA  interference  experiment:  A  human  PAX6-specific
double-stranded small interfering (si)RNA was synthesized
(Silencer Select Pre-Designed siRNA ID#s10067; Ambion,
Austin, TX). A lipid transfection system (siPORT NeoFX
transfection agent; Ambion) was used to introduce siRNAs
into Y-79 and WERI cells via the following protocol: cells
were preincubated with or without 10 μg/ml CN-A for 24 h,
after which they were resuspended at a density of 106 cells/ml
growth medium. One milliliter was seeded in duplicate into
24 wells (CELLSTAR®). The mixtures of siRNA and lipid
reagent were added to 106 cells at a final concentration of 100
nM. Thereafter, cells were treated with or without 10 μg/ml
CN-A  for  48  h.  Reverse  transcriptase  (RT)–PCR  was
conducted as described above.
RESULTS
Cotylenin A inhibition of cell growth in two retinoblastoma
cell lines: To determine if CN-A inhibits cell growth, we
investigated the cell viability of two retinoblastoma cell lines,
Y-79 and WERI, in growth medium with 0, 10, and 20 μg/ml
CN-A for 0, 3, and 7 days (Figure 1). At 10 and 20 μg/ml, CN-
A significantly repressed the proliferation compared to 0 μg/
ml in two cell lines. At 10 and 20 μg/ml CN-A for 3 and 7
days, Y-79 and WERI cell growth increased compared to
control.
Cotylenin A induction of apoptosis in two retinoblastoma cell
lines: CN-A has been reported to induce apoptosis in human
lung carcinoma cells [13]. To investigate whether CN-A also
induces  apoptosis  in  a  retinoblastoma  cell,  we  examined
retinoblastoma cell lines cultured with or without 10 μg/ml
CN-A for 7 days in noncoated tissue culture vessels using a
TUNEL  assay  (Figure  2A,B)  and  western  blot  analysis
(Figure  2C).  CN-A  treatment  increased  the  number  of
TUNEL-positive cells threefold compared to untreated cells
in the two cell lines (Figure 2B). Cleaved PARP can be used
as a marker of the early stages of apoptosis because the PARP
protein is cleaved by caspase-3 when apoptosis is induced
[20,21],  with  nuclear  condensation  and  fragmentation  of
chromosomal DNA occurring in the final stage of apoptosis
Figure 1. Cell growth response in retinoblastoma cell lines. The response of cotylenin A (CN-A) on retinoblastoma cell growth was examined
using fluorescence cell viability assays repeated in triplicate. Retinoblastoma cells were treated with CN-A at concentrations of 0, 10, or 20
μg/ml and incubated for 0, 3, and 7 days (n=3); the error bar indicates the standard deviation. Asterisks indicate significant differences when
compared with the control without CN-A (*p<0.01; **p<0.05).
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973Figure 2. Response of cotylenin A on
cell  death  and  apoptosis  in
retinoblastoma cell lines. A: Detection
of  apoptosis  using  a  terminal
deoxynucleotidyl  transferase
deoxyuridine  5′-triphosphate  (dUTP)
nick-end labeling (TUNEL) assay. Cells
were treated with or without 10 μg/ml
cotylenin A (CN-A) for 7 days. The bar
represents 25 μm. The arrow points to
TUNEL-positive cells. B: The bar graph
indicates  the  percentage  of  TUNEL-
positive  cells.  Asterisks  indicate
significant differences when compared
with the control without CN-A (p<0.05;
C)  the  bar  graph  and  electrophoresis
photographs  indicate  the  protein
expression of cleaved- Poly Adenosine
diphosphate  –ribose  polymerase
(PARP) in retinoblastoma cells. The bar
graph  indicates  C-PARP  protein
expression (n=3); the error bar indicates
the  standard  deviation.  Asterisks
indicate  significant  differences  when
compared with the control without CN-
A (p<0.05).
Molecular Vision 2010; 16:970-982 <http://www.molvis.org/molvis/v16/a107> © 2010 Molecular Vision
974Figure  3.  Photographs  of  the
morphology of retinoblastoma cell lines
with  and  without  cotylenin  A.  A:
Photographs  indicate  morphology  of
retinoblastoma cells with or without 10
μg/ml  CN-A  for  2  days.  The  bars
indicate the length of 25 μm. B: The
graph  indicates  the  percentage  of  the
dendrite-like process cells (mean±SD,
n=3).  Asterisks  indicate  significant
differences  when  compared  with  the
control without CN-A (*p<0.05).
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975Figure  4.  Expression  of  mRNA  and
protein in retinoblastoma cells. A: Some
gene  mRNA  expression  was
investigated using reverse transcription
polymerase chain reaction (RT–PCR).
Cells were treated with or without 10
μg/ml cotylenin A (CN-A) for 3 days.
The numbers (0, 10, and 20) indicate
CN-A concentrations (μg/ml). β-Actin
mRNA was used as an internal control.
B:  Some  protein  expression  was
investigated using western blot analysis
in  retinoblastoma  cells.  Cells  were
treated with or without 10 μg/ml CN-A
for 5 days. “Cont.” indicates the non-
treatment. “CN-A” indicates the CN-A
treatment (10 μg/ml). β-Tubulin protein
was used as a loading control. C: The
bar graph indicates the PAX6 protein
expression (n=3); the error bar indicates
the standard deviation.
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976[22]. Cleaved-PARP proteins in two retinoblastoma cell lines
accumulated (Figure 2C).
Cotylenin  A-induced  morphological  change  in  two
retinoblastoma  cell  lines:  To  investigate  whether  CN-A
caused morphological changes to retinoblastoma cells, we
observed two retinoblastoma cell lines cultured with 10 μg/ml
CN-A for 7 days in poly-D-lysine-coated tissue culture vessels
(Figure 3) to allow adherence of the retinoblastoma cells,
which are normally cultured in suspension. CN-A induced
morphological changes in Y-79 and WERI cells, including the
appearance  of  dendrite-like  processes  (Figure  3A,  right).
Figure 3B shows the percentage of the dendrite-like process
cells at 0, 2, 4, 6, and 8 days with CN-A treatment. The
percentage of the morphologically changed cells increased
significantly by CN-A. At 2 days, the percentage was maximal
for  both  Y-79  and  WERI  cells.  The  percentage  of
morphologically changed cells gradually declined at 4, 6, and
8 days.
Cotylenin  A  induced  and  decreased  gene  expression:  We
postulated that CN-A induced mRNA and protein expression
of some genes in two retinoblastoma cell lines (Figure 4). N-
myc  has  been  reported  to  be  expressed  in  retinoblastoma
tumors and fetal retinas (but not adult retinas) [23] and to
decrease during differentiation of neuroblastoma [24] and
Figure 5. Luciferase assay of paired box gene 6 (PAX6) promoter activity. A: Schematic indicates the representation of the PAX6 transcript
unit in humans. The boxes denote exons. Braces indicate the extent of P0, P1, and Pα promoters in the PAX6 gene area. B: Luciferase assay
of P0, P1, and Pα promoter activity in Y-79 cells. C: Luciferase assay of P0, P1, and Pα promoter activity in WERI cells. P0 of pGL4.10 insert
indicates the insertion of P0 promoter sequences (5315 bp), P1 promoter activity (3796 bp), and Pα promoter sequences (3628 bp). White and
black squares indicate the no-CN-A treatment and CN-A treatment, respectively. The negative pGL4.10 insert indicates an empty sequence.
The data are presented after normalizing transfection efficiency using the Renilla luciferase reporter gene (n=3); the error bar indicates the
standard deviation; Mann–Whitney U-test, *p<0.05.
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977retinoblastoma cell lines [25]. In Y-79 and WERI cells, CN-
A reduced N-myc mRNA and protein expression. P21 has
been reported to regulate cell-cycle progression at G1 [26]. In
Y-79 and WERI cells, CN-A induced P21 mRNA and protein
expression. PAX6, a highly conserved transcription factor in
vertebrates,  is  crucial  for  the  development  of  the  central
nervous  system,  eye,  nose,  pancreas,  and  pituitary  gland
(reviewed in [27]). In Y-79 and WERI cells, CN-A induced
PAX6 mRNA expression. In two cell lines, few increases of
PAX6 protein expression were detected; however, significant
increases of PAX6 protein were not detected at p<0.05 (Figure
4C). RHO is a rod photoreceptor marker gene [28]. RHO
expression increased in CN-A-treated Y-79 and WERI cells
compared to untreated cells. In two cell lines, alternation of
RHO protein expression was not detected.
Cotylenin A-induced PAX6 promoter activity in two cell lines:
Three  promoters  of  PAX6  (P0,  P1,  and  Pα)  have  been
identified (reviewed in [29]; Figure 5A). To confirm whether
CN-A  activates  the  PAX6  promoter,  we  investigated  the
luciferase activity of the promoters in two retinoblastoma cell
lines after 48 h treatment with 10 μg/ml CN-A. In Y-79 and
WERI cells, the P0 and P1 promoters were activated without
CN-A treatment. With CN-A treatment the luciferase activity
of only the PAX6 P1 promoters increased compared to that of
the untreated control in Y-79 (Figure 5B). In WERI cells the
luciferase activity of the three promoters with CN-A increased
compared to that of the untreated control (Figure 5C).
Cotylenin A-induced Δexon5 PAX6 mRNA in WERI cells: The
Pα promoter transcript has been reported to encode paired
domain-less (ΔPD) PAX6 [30,31]. To confirm whether CN-A
treatment induced the expression of spliced PAX6 variants,
we  used  RT–PCR  with  various  primer  sets  to  investigate
transcription products. The PAX6 (exons 11–13) primer set
gave results similar to that shown in Figure 4A. The shift-
down PAX6 (exons 3–6) mRNA band in WERI cells with CN-
A treatment was detected (Figure 6). This shift-down mRNA
band sequencing revealed the loss of exon 5 (position 544–
674  in  NM_000280).  We  termed  these  spliced  variants
Δexon5  PAX6  mRNA.  However,  in  Y-79  cells,  Δexon5
PAX6 mRNA expression was not detected.
Increase and decrease in the pattern of cotylenin A-induced
mRNA expression of PAX6 and RHO: To further study the
regulatory effect of PAX6 on RHO expression, we conducted
PAX6 RNA interference experiments (RNAi). Endogenous
PAX6 mRNA was knocked down by the RNAi technique to
verify  a  regulatory  correlation  between  PAX6  and  RHO
expression. RT–PCR showed that PAX6 siRNA significantly
knocked down PAX6 mRNA expression in transfected cells
with CN-A treatment in both Y-79 and WERI cells (Figure
7). RHO mRNA expression levels with PAX6 siRNA and CN-
A decreased and were similar to PAX6 mRNA expression
levels  in  both  Y-79  and  WERI  cells.  In  contrast,
glyceraldehyde-3-phosphate  dehydrogenase  mRNA
expression showed no change. The mRNA expression level
of PAX6 and RHO in retinoblastoma cells with PAX6 siRNA
and without CN-A decreased compared to control; however,
this  expression  level  showed  no  significant  difference  at
p<0.05.
Cotylenin A did not have the ability of a histone deacetylase
inhibitor: Some differentiation agents have been known to
exert histone deacetylase inhibitor activity (reviewed in [32]).
In  retinoblastoma  cell  lines,  sodium  butyrate  has  been
reported to be the histone deacetylase inhibitor agent to have
the ability of differentiation agents [33,34]. Therefore, we
next examined cellular levels of acetylated histone H3 and H4
in the presence or absence of CN-A treatment. Western blot
analysis showed that the accumulation of acetylated H3 and
H4  in  Y-79  and  WERI  cells  were  unchanged  by  CN-A
treatment (Figure 8).
DISCUSSION
We showed that CN-A inhibits cell proliferation and induces
cell death in two retinoblastoma cell lines (Figure 1 and Figure
2) as it does in other tumor cell lines [13–15,35]. Cleaved
PARP western blot analysis results (Figure 2C) suggest that
CN-A-induced apoptosis of retinoblastoma cells is caspase
Figure 6. The mRNA expression of paired box gene 6 (PAX6) spliced variants in retinoblastoma cell lines. Cells were treated with or without
10 μg/ml CN-A for 3 days. “Cont.” indicates the non-treatment. “CN-A” indicates the CN-A treatment (10 μg/ml). β-Actin mRNA was used
as an internal control.
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978mediated.  These  results  indicated  that  the  response  of
retinoblastoma cells to CN-A is similar to that of other tumor
cells [13,16].
CN-A induced Y-79 and WERI cells to exhibit dendrite-
like processes (Figure 3, right), an effect similar to that of
other  differentiation  reagents  [25,33,36].  CN-A  may
dynamically  change  cell  adhesion  and  cytoskeleton
conformation of the retinoblastoma cell lines Y-79 and WERI
cells.  The  elongation  of  CN-A  induced-dendrite-like
processes was not detected with continuous observation. In
addition, the number of dendrite-like process cells gradually
declined.  With  continuous  observations,  morphologically
changed cells were found to die. Therefore, the morphological
change by CN-A may be related to CN-A-induced apoptosis.
CN-A reduced the expression of the oncogene N-myc, a
neuroblastoma marker that has been reported to be expressed
in  retinoblastoma  tumors  and  fetal  retinas  (but  not  adult
retinas) [23], and to decrease during the differentiation of
neuroblastoma [24] and retinoblastoma cell lines [25]. This
suggests that the neurotumor state of retinoblastoma cell lines
changes by CN-A.
CN-A increased the mRNA and protein expression of
P21 in Y-79 and WERI cells (Figure 4A,B). P21 protein has
been reported to regulate cell-cycle progression at G1 [26]. In
Y-79 and WERI cells, CN-A is considered to induce not only
apoptosis but also cell-cycle inhibition.
CN-A increased the mRNA expression of PAX6 in Y79
and WERI cells (Figure 4A). PAX6 has been reported to play
multiple roles in both lens and retinal development [37] and
is required for the proliferation and expansion of retinal stem
cells [38]. Three promoters of PAX6 (P0, P1, and Pα) have
been identified (reviewed in [29]; Figure 5A). In addition,
PAX6 has three isoforms: normal PAX6, PAX6 (5a), and
paired domain-less (ΔPD)PAX6. The P0 and P1 promoter
transcripts have been reported to encode normal PAX6 and
PAX6  (5a)  splice  variants.  It  has  been  reported  that
(ΔPD)PAX6 mRNA is transcribed by activation of the Pα
promoter [30,31]. CN-A-induced PAX6 splice variant mRNA
expression  patterns  also  differed  between  the  two
retinoblastoma cell lines, corresponding to activation of three
PAX6 promoters by CN-A (Figure 6). Normal PAX6 mRNA
translated into a 47-kDa protein with 422 amino acids. The
Figure 7. Response of paired box gene 6 (PAX6) knockdown on rhodopsin (RHO) expression inretinoblastoma cell lines. PAX6 siRNA was
introduced into Y-79 and WERI cells via siPORT for knockdown of PAX6 mRNA. The electrophoresis photographs and the bar graphs indicate
the result of reverse transcription polymerase chain reaction (RT–PCR) in Y-79 cells (A) and WERI cells (B). PAX6 and RHO mRNA
expression were investigated using RT–PCR. The mRNA expression was detected 48 h after siRNA transfection and cotylenin A (CN-A)
treatment. The bar graph indicates transduction of PAX6, RHO, and GAPDH mRNA expression by PAX6 siRNA (n=3); the error bar indicates
the standard deviation; Mann–Whitney U-test, *p<0.05, **p<0.01.
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979mass of the deduced amino acid of Δexon5 PAX6 mRNA was
about 32 kDa and contained 286 amino acids. It is presumed
that the deduced amino acid of Δexon5 PAX6 is (ΔPD)PAX6
proteins [29]. Δexon5 PAX6 mRNA expression in WERI was
considered to be transcribed by PAX6 Pα promoter activity.
A western blot investigation on the expression of the Δexon5
PAX6 protein induced by CN-A in WERI cells showed that
the mass of the deduced amino acid of Δexon5 PAX6 mRNA
was not detected with or without CN-A-treatment (data not
shown).  Overexpression  of  (ΔPD)-PAX6  causes  a  severe
microphthalmic phenotype due to apoptotic cell death in the
lens during embryonic development [31,37]. Little is known
about  the  molecular  mechanism  and  function  of  (ΔPD)-
PAX6. We attempted to overexpress the Δexon5 PAX6 mRNA
in WERI cells; however, RHO gene expression change was
not  detected  (data  not  shown).  The  (ΔPD)-PAX6  mRNA
expression  in  WERI  cells  by  CN-A  may  be  related  to
apoptosis or another cell physiology. The different response
to CN-A on PAX6 transcription in two retinoblastoma cell
lines  is  unique.  CN-A  may  be  useful  in  researching  the
expression of PAX6 splice variants.
RHO is a rod photoreceptor marker gene [28] that is
modulated by PAX6 in Drosophila [39]. In Y-79 and WERI
cells, CN-A induced RHO mRNA expression (Figure 4A) but
it did not induce RHO protein expression (Figure 4B). In the
PAX6 siRNA experiment in Y-79 and WERI cells with CN-
A  treatment,  the  expression  pattern  of  PAX6  mRNA  was
similar  to  that  of  RHO  mRNA  (Figure  7).  These  results
indicate that PAX6 mRNA expression may participate in the
expression of RHO. CN-A-induced PAX6 is considered to
modulate the expression of RHO mRNA. In addition, CN-A
may  induce  rod  photoreceptor  differentiation  in
retinoblastoma cell lines.
The  reagents  that  promote  the  differentiation  of
retinoblastoma cell lines include retinoic acid (RA)-induced
cone photoreceptor-specific genes in WERI cells [35]. RA has
been  used  in  combination  with  other  reagents  to  induce
photoreceptor differentiation of embryonic stem cells [40].
Butyrate has been reported to induced Recoverin, the rod
photoreceptor marker gene, mRNA, and protein in Y-79 cells
[41]  and  dibutyryl  cyclic  adenosine  3′,  5′-monophosphate
(AMP) and butyrate-induced morphological changes in Y-79
cells [25,33]. In particular, butyrate has been reported to be a
histone deacetylase inhibitor agent [32,33]. However, CN-A
does  not  have  the  ability  to  inhibit  histone  deacetylase.
Treatment with a combination of CN-A and vitamin D3 is
reported to be more effective than treatment with CN-A or
vitamin  D3  alone  in  inducing  the  differentiation  of  acute
monocytic leukemia cells [42]. The effect of CN-A appears
to involve a more diverse array of factors compared to other
differentiation-inducing  reagents.  These  previous  reports
have indicated that the effects of CN-A in retinoblastoma cell
lines can be extrapolated to other cytokines or differentiation-
inducing regents, including RA, butyrate, and dibutyryl cyclic
AMP.
In summary, we found that CN-A is a potent inhibitor of
cell  proliferation  and  apoptosis,  and  it  changes  tumor
characteristics in retinoblastoma cell lines. Differences in the
effect  of  CN-A  on  ocular  retinoblastoma  tumors  and
metastatic tumors were observed. CN-A may be useful in
researching PAX6 splice variants. The effect of CN-A on
retinoblastoma cells indicates that CN-A may have distinct
functions beyond what we have reported here. Further work
is  required  to  elucidate  the  mechanisms  underlying  these
novel observations.
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Figure  8.  The  accumulation  of
acetylated histone H3 and H4 protein in
retinoblastoma cell lines. Western blot
analysis of acetylated histone H3 and H4
(acetyl-H3  and  H4)  protein  levels  in
retinoblastoma cells treated with (+) or
without (–) cotylenin A (CN-A) for 5
days.  β-Actin  was  used  as  a  loading
control.
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